Log in
Enquire now
Affimed Therapeutics

Affimed Therapeutics

A company developing immunotherapies for the treatment of cancer

OverviewStructured DataIssuesContributors

Contents

affimed.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Therapy
Therapy
Biopharmaceutical
Biopharmaceutical
Oncology
Oncology
Therapeutics
Therapeutics
Cancer immunotherapy
Cancer immunotherapy
Immunotherapy
Immunotherapy
Cancer
Cancer
...
Location
Heidelberg
Heidelberg
B2X
B2B
B2B
CEO
‌
Adi Hoess
AngelList URL
angel.co/affimed-therapeutics
Pitchbook URL
pitchbook.com/profiles.../54789-67
Legal Name
Affimed N.V.
Number of Employees (Ranges)
51 – 200
Email Address
info@affimed.com
Phone Number
+496221674360
Full Address
Technologiepark Im Neuenheimer Feld 582 69120 Heidelberg, Germany
Investors
Aeris Capital
Aeris Capital
Novo Nordisk
Novo Nordisk
Founded Date
2000
Fax Number
+49 (0)6221 6743-649
Total Funding Amount (USD)
26,512,000
Latest Funding Round Date
April 29, 2010
Competitors
Gamida Cell
Gamida Cell
Exchange
Nasdaq
Nasdaq
CFO
Latest Funding Type
Series C
Series C
Patents Assigned (Count)
4
COO
Wellfound ID
affimed-therapeutics
Country
Germany
Germany

Other attributes

CFO of
Affimed
Affimed
Company Operating Status
Active
COO of
Affimed
Affimed
Ticker Symbol
AFMD
Wikidata ID
Q30255337

Affimed is a publicly traded, clinical stage biopharmaceutical company based in Heidelberg, Germany. It focuses discovering and developing targeted immuno-oncology therapies. Founded in 2000 by a group led by Professor Melvyn Little at the German Cancer Research Center (DKFZ), Affimed has a number of clinical and pre-clinical programs in development based on its ROCK (Redirected Optimized Cell Killing) platform and its tetravalent bispecific immune cell engagers.

The ROCK platform allows for antibody engineering of highly customizable NK and T-cell engagers to generate clinical candidates tailored to multiple disease indications and settings.

Affimed has three programs under the innate cell engagers area, AFM 13, AFM 24, and AFM 26. AFM13 is a treatment aimed at treating Hodgkin Lymphoma. There are several studies running in this program, where it is being tested by itself and in combination with other therapeutics. The studies are at various stages of development from pre-IND to Phase 2. AFM24 is a potential treatment for solid tumors that is in the pre-IND stage. AFM 26 is another potential treatment for multiple myeloma which is in the pre-IND stage. This program is being conducted in partnership with another pharmaceutical company.

In the T-Cell engager area, Affimed has two product candidates, AFM11 and AMV564 (Amphivena). AFM11 is aimed as a therapeutic for non-hodgkin lymphoma and acute lymphocytic leukemia. It is Phase 1 clinical studies for both types of cancers. Amphivena is also a therapeutic targeting acute myeloid leukemia and is in Phase 1 of clinical studies. This program, however, is licensed by Affimed from another company.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets

Affimed N.V.

https://globenewswire.com/news-release/2018/08/27/1557198/0/en/Affimed-Announces-Collaboration-with-Genentech-to-Develop-Novel-NK-Cell-Engager-based-Immunotherapeutics-for-Multiple-Cancer-Targets.html

Web

References

Find more companies like Affimed Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.